Georges Azzi

875 total citations
14 papers, 403 citations indexed

About

Georges Azzi is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Georges Azzi has authored 14 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Cancer Research and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Georges Azzi's work include Cancer Genomics and Diagnostics (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). Georges Azzi is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). Georges Azzi collaborates with scholars based in United States, Spain and Brazil. Georges Azzi's co-authors include Fabio A.B. Schutz, Toni K. Choueiri, Youjin Je, Paul L. Nguyen, Harold J. Burstein, Erica L. Mayer, Jonathan E. Rosenberg, Joaquim Bellmunt, Michel Velez and Rachel E. Lerner and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Georges Azzi

13 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Georges Azzi United States	7	235	159	89	88	71	14	403
Ahmet Demirkazık Türkiye	12	193 0.8×	43 0.3×	222 2.5×	71 0.8×	38 0.5×	29	426
Mariam Jafri United Kingdom	8	64 0.3×	74 0.5×	102 1.1×	87 1.0×	124 1.7×	15	354
John C. Champion United States	6	117 0.5×	224 1.4×	76 0.9×	106 1.2×	16 0.2×	9	358
Kokoro Kobayashi Japan	11	205 0.9×	18 0.1×	106 1.2×	45 0.5×	138 1.9×	39	341
P. Reinecke Germany	10	83 0.4×	70 0.4×	76 0.9×	139 1.6×	37 0.5×	35	418
Timothy Spiro United States	10	151 0.6×	90 0.6×	100 1.1×	65 0.7×	25 0.4×	22	308
Chika Shigemori Japan	5	87 0.4×	23 0.1×	37 0.4×	102 1.2×	55 0.8×	8	359
G.F. Samelis Greece	10	247 1.1×	68 0.4×	159 1.8×	54 0.6×	24 0.3×	23	372
Emma Zattarin Italy	11	291 1.2×	20 0.1×	174 2.0×	114 1.3×	120 1.7×	41	500

Countries citing papers authored by Georges Azzi

Since Specialization

Citations

This map shows the geographic impact of Georges Azzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georges Azzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georges Azzi more than expected).

Fields of papers citing papers by Georges Azzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georges Azzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georges Azzi. The network helps show where Georges Azzi may publish in the future.

Co-authorship network of co-authors of Georges Azzi

This figure shows the co-authorship network connecting the top 25 collaborators of Georges Azzi. A scholar is included among the top collaborators of Georges Azzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georges Azzi. Georges Azzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Chakrabarti, Sakti, Stacey A. Cohen, Antony Tin, et al.. (2024). Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.. Journal of Clinical Oncology. 42(3_suppl). 212–212. 1 indexed citations

Recio, Fernando O., Brian Orr, Young Kwang Chae, et al.. (2023). Immunotherapy response monitoring using personalized circulating tumor DNA analysis in patients with relapsed gynecologic malignancies (2297). Gynecologic Oncology. 176. S313–S314. 1 indexed citations

Vidula, Neelima, Shumei Kato, Caroline Weipert, et al.. (2022). Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer. npj Breast Cancer. 8(1). 117–117. 8 indexed citations

Grzankowski, K.S., Concepcion Diaz‐Arrastia, Georges Azzi, et al.. (2022). ctDNA in treatment response monitoring in patients with relapsed gynecologic malignancies.. Journal of Clinical Oncology. 40(16_suppl). e17501–e17501.

Azzi, Georges, Antony Tin, Meenakshi Malhotra, et al.. (2022). Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report. SHILAP Revista de lepidopterología. 15(2). 473–479. 7 indexed citations

Azzi, Georges, Mehrad Tavallai, Vasily N. Aushev, et al.. (2022). Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The Oncologist. 28(3). 220–229. 6 indexed citations

Drusbosky, Leylah, Mehmet Asım Bilen, Georges Azzi, et al.. (2021). Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.. Journal of Clinical Oncology. 39(15_suppl). 3040–3040. 13 indexed citations

Percent, Ivor, Craig H. Reynolds, Kartik Konduri, et al.. (2020). Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).. Journal of Clinical Oncology. 38(15_suppl). TPS9635–TPS9635. 12 indexed citations

Azzi, Georges, Antony Tin, Meenakshi Malhotra, et al.. (2020). 25 Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring. SHILAP Revista de lepidopterología. A13.2–A14. 1 indexed citations

10.

Azzi, Georges, et al.. (2014). Isocitrate dehydrogenase mutations in chondrosarcoma. Current Opinion in Oncology. 26(4). 403–407. 10 indexed citations

11.

Choueiri, Toni K., Erica L. Mayer, Youjin Je, et al.. (2011). Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. Journal of Clinical Oncology. 29(6). 632–638. 226 indexed citations

12.

Schutz, Fabio A.B., Youjin Je, Georges Azzi, Paul L. Nguyen, & Toni K. Choueiri. (2010). Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology. 22(6). 1404–1412. 113 indexed citations

13.

Schutz, Fabio A.B., Youjin Je, Georges Azzi, & Toni K. Choueiri. (2010). Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials.. Journal of Clinical Oncology. 28(15_suppl). 4602–4602. 2 indexed citations

14.

Azzi, Georges, Fabio A.B. Schutz, Youjin Je, & Toni K. Choueiri. (2010). Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients.. Journal of Clinical Oncology. 28(15_suppl). 4609–4609. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact